Caplin Point Laboratories growth over the years

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Compounded a year	1 yr	3 yr
Revenue	+12.9%	+14.2%
EBITDA	+17.6%	+19.9%
Net Income	+20.1%	+19.9%
EPS (adj.)	+13.8%	+19.4%
Total Assets	+26.1%	+22.7%
Total Equity	+25.8%	+23.9%
Free Cash Flow	+14.2%	+52.3%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

CAPLIPOINT₹2,376.10

Caplin Point Laboratories Ltd.

· Pharma & Health

₹ CrorePeersAJANTPHARM ERIS GLAND BLUEJET CONCORDBIO ACUTAAS EMCURE GRANULESMcap ₹18,058 Cr

Annuals · FY-end closes

Compounded Growth Annuals · CAGR %	1Y CAGR	3Y CAGR
Revenue	+12.9	+14.2
EBITDA	+17.6	+19.9
Net Income	+20.1	+19.9
EPS (adj.)	+13.8	+19.4
Total Assets	+26.1	+22.7
Total Equity	+25.8	+23.9
Free Cash Flow	+14.2	+52.3

CAGR from filed annuals — needs positive start & end values.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.